Uromigos-Kidney Cancer
Advertisement
Dr. Andrew Smith, chair of diagnostic imaging at St. Jude's, joins the podcast to discuss the emerging field of radiomics.
Listen to the podcast format of the kidney cancer panel on IO after IO therapy from Uromigos Live 2024.
Listen to the podcast format of the kidney cancer panel on TKI vs Ipi/Nivo vs IO/TKI from Uromigos Live 2024.
Tom and Brian finish discussing bladder and kidney cancer highlights from ESMO 2024.
Lothar Bergmann describes this investigator-initiated trial of Ipi/Nivo vs SOC in Non-clear Cell RCC.
Brad McGregor joins Brian and Tom to discuss a new HIF inhibitor, NKT2152, and preliminary data in RCC.
Drs. Cristina Suárez, Elena Castro, and María Teresa Bourlon discuss recent ESMO guideline changes on GU cancers.
Naomi Haas joins Tom and Brian in New York City at the World GU Conference to discuss several RCC topics.
Dr. Eric Jonasch discusses the process of guideline modification and updates in adjuvant, front-line and refractory RCC.
Dr. David Braun discusses his organization of immune therapies into four groups and describes novel treatments and targets.
Drs. Cristina Suárez, Elena Castro, and María Teresa Bourlon host the first Spanish-language ASCO episode for The Uromigos.
Drs. Axel Bex, Christian Blank, Laura Mertens and Micheil Van der Heijden get a chance to win The Uromigos Cup.
Drs. Viktor Grünwald, Boris Hadaschik and Gunhild Von Amsberg answer trivia for the Uromigos Cup qualifying round.
Drs. Nobuaki Matsubara, Hiroshi Kitamura and Yuji Miura answer trivia questions set by Tom and Brian for the Uromigos Cup.
Drs. Danny Heng, Christian Kollmannsberger and Kala Sridhar attempt to take on Team LA to win the Uromigos Cup.
Silke Gillessen joins Brian and Tom to give a preview of this year's ASCO annual meeting.
The Uromigos discuss adjuvant therapy in kidney and bladder cancer trials including KEYNOTE-564.
Dr. McDermott discusses the similarities between current melanoma trials and kidney cancer treatments.
Dr. Bergerot describes her modifications of existing quality of life models, and Tom explains LITESPARK-005's QoL data.
Dr. Pedro Barata gives an overview of the CheckMate 914 trial on adjuvant nivolumab plus ipilimumab for localized RCC.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.